Sarepta Therapeutics (SRPT) EBT Margin (2017 - 2025)
Historic EBT Margin for Sarepta Therapeutics (SRPT) over the last 12 years, with Q2 2025 value amounting to 25.14%.
- Sarepta Therapeutics' EBT Margin rose 214000.0% to 25.14% in Q2 2025 from the same period last year, while for Jun 2025 it was 20.17%, marking a year-over-year increase of 160400.0%. This contributed to the annual value of 13.71% for FY2024, which is 555400.0% up from last year.
- Latest data reveals that Sarepta Therapeutics reported EBT Margin of 25.14% as of Q2 2025, which was up 214000.0% from 26.08% recorded in Q4 2024.
- In the past 5 years, Sarepta Therapeutics' EBT Margin registered a high of 26.08% during Q4 2024, and its lowest value of 202.25% during Q1 2023.
- For the 5-year period, Sarepta Therapeutics' EBT Margin averaged around 40.15%, with its median value being 25.29% (2021).
- In the last 5 years, Sarepta Therapeutics' EBT Margin tumbled by -1528500bps in 2023 and then skyrocketed by 2122800bps in 2024.
- Over the past 5 years, Sarepta Therapeutics' EBT Margin (Quarter) stood at 60.5% in 2021, then soared by 35bps to 39.2% in 2022, then soared by 126bps to 10.17% in 2023, then soared by 156bps to 26.08% in 2024, then fell by -4bps to 25.14% in 2025.
- Its last three reported values are 25.14% in Q2 2025, 26.08% for Q4 2024, and 7.28% during Q3 2024.